The Serum Institute of India (SII) says it might promote the AstraZeneca vaccine to the nation’s state governments at 400 rupees ($5.30) per dose and to non-public hospitals at 600 rupees ($7.95), because the central authorities continues to obtain the vaccine at 150 rupees ($2).

“Moreover, owing to the complexity, and urgency of the scenario it’s difficult to produce it independently to every company entity,” it stated in a press release on Wednesday.

“We might urge all company and personal people to entry the vaccines by the state facilitated equipment and personal well being programs.”

SII, the world’s largest vaccine maker, sells the AstraZeneca vaccine in India below the Covishield model title.

On Monday, the Indian authorities stated it would open its vaccination drive to all adults from Might 1, with 50 p.c of vaccine doses reserved for the federal authorities and the remainder to be divided between states and personal hospitals.

The SII’s announcement got here as new coronavirus infections and deaths set fresh records in India.

Authorities registered roughly 295,000 recent instances and a pair of,023 deaths within the final 24 hours, based on well being ministry knowledge. Each had been highest-ever single-day tallies.


As quickly because the SII introduced its costs, a senior politician and former federal minister belonging to the primary opposition Congress social gathering criticised the federal government, saying the totally different costs for states “will bleed dry the already reeling state funds”.

“We demand one nation, one worth for centre and state authorities,” Jairam Ramesh tweeted on Wednesday.

High Congress chief Rahul Gandhi had additionally accused the federal government of pursuing a “discrimination” and never a “distribution technique” when it got here to vaccinating all adults.

“No free vaccines for 18-45 yr olds. Middlemen introduced in with out worth controls. No vaccine assure for weaker sections. GOI’s Vaccine Discrimination – Not Distribution – Technique!” Gandhi tweeted on Tuesday.

Well being consultants have additionally expressed concern over whether or not tens of millions of India’s poor will be capable of get themselves vaccinated.

“Each particular person, notably low-income households, needs to be lined … They shouldn’t be disadvantaged of the possibility to get vaccination as a result of individuals from high-income households can go and buy from the market. It’s completely vital that no particular person is disadvantaged of the possibility to get the vaccine solely on the grounds of affordability,” Okay Srinath, president of the Public Well being Basis of India, instructed Al Jazeera.

India kicked off its inoculation drive in mid-January and has administered greater than 127 million pictures up to now.

Some native authorities have nonetheless been operating in need of provides, and India has put the brakes on exports of the AstraZeneca shot.

“For the time being, there’s not sufficient vaccine to satisfy the present requirement. Though the federal government of India has indicated that from Might 1 they will vaccinate [all above the age of 18], to my pondering it would take some extra time as a result of these [vaccine] preparations should be made first,” Lalit Kant, former head of the division of epidemiology on the Indian Council of Medical Analysis (ICMR), instructed Al Jazeera.

In the meantime, India’s Bharat Biotech stated on Tuesday it’s scaling up manufacturing of its homegrown Covaxin vaccine to 700 million doses per yr.

Covaxin is being administered alongside AstraZeneca’s shot in India, whereas approval has additionally been given for Russia’s Sputnik V.

J&J seeks native trial approval

In a associated improvement, Johnson & Johnson firm on Tuesday stated it’s searching for to conduct an area medical trial in India for its single-dose COVID-19 vaccine, which was paused in the USA final week on reviews of uncommon blood clots.

The corporate stated it had submitted an utility to India’s drug regulator – the Medicine Controller Common of India – requesting approval for the “bridging” security and immunogenicity research for its vaccine.

The worldwide rollout of the single-dose vaccine, which is seen as an important weapon within the battle in opposition to the COVID-19 pandemic, obtained a jolt when US federal well being companies final Tuesday advisable pausing its use.

J&J’s India utility, which the corporate stated was to adjust to native laws, comes because the nation grapples with a second wave in COVID-19 instances that has severely strained its well being system and brought on shortages of oxygen and medicines.

Final week, India stated it might fast-track emergency approvals for foreign-made COVID-19 vaccines, a transfer that might exempt firms from finishing up “bridging” trials for his or her vaccines.

Johnson & Johnson didn’t instantly give extra particulars concerning the course of.

Bilal Kuchay contributed to this report from New Delhi, India